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Case
number
Proteinuria
g/d
S creat at
diagnosis,
mg/dl
cGVHD
yes/no
Biopsy
result
Treatment Rx
result
1 10.20 0.98 Yes MGN PDN,Tacro,
MMF
CR
2 1.67 1.17 No MGN PDN,Tacro CR
3 5.02 1.26 Yes MCD PDN,Tacro CR
4 2.04 2.96 Yes Tubulitis PDN CR
5 8.48 0.89 Yes MGN PDN,Tacro,
Siro
NR
6 1.57 2.6 Yes MGN PDN,MMF NR
7 0.61 0.8 Yes FSGS PDN,CsA CR
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sone (>0.5mg/kg) but only one had complete remission
with single agent prednisone. Other immunosuppressant
including Rituximab, Tacrolimus, Sirolimus, Cyclosporine,
MMF and Rituxan were used for non-responders to predni-
sone. Time and response to resolution to proteinuria was
variable as shown in the table below. No patients progressed
to ESRD and two patients had died as of the last follow up.
Conclusions: Our data conﬁrm the association of NRP with
chronic GVHD. Monitoring for proteinuria and timely
recognition of this entity may avoid the need for sustained
immunosuppression and nephronal loss.412
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Introduction: In the last two decades, there have been
multiple reasons for the improved outcomes of patients
undergoing allogeneic HSCT including more precise HLA
matching, the advent of reduced intensity conditioning
regimens, use of novel antimicrobial agents, increased op-
tions for immunosuppression and better patient selection.
However, the collective impact of these advances on out-
comes of patients who develop grade III or IV acute GVHD
remains unclear.
Methods: We performed a retrospective analysis of 428
patients with grade III or IV acute GVHD treated at Massa-
chusetts General Hospital and Dana-Farber Cancer Institute
from 1997-2012. We compared overall survival (OS), pro-
gression-free survival (PFS) from underlying disease, and
GVHD-related mortality (GRM) in 3 cohorts based on the
year of transplantation: 1997-2001 (n¼111), 2002-2006
(n¼112), and 2007-2012 (n¼205) using multivariate analysis
adjusting for age, diagnosis, disease status at transplant,
grade of acute GVHD, performance status, comorbidities,
conditioning intensity, HLA match, donor source, and donor-
patient gender match.Results: The most recent cohort of patients with grade III or
IV acute GVHD (2007-2012) was signiﬁcantly older (31%> 60
in 2007-2012, 12% > 60 in 2002-2006, and 4% > 60 in 1997-
2001, p < 0.001), and had lower proportion (35%) of grade IV
acute GVHD compared to earlier cohorts (52% in 1997-2001,
and 38% in 2002-2006, p¼ 0.01). The use of reduced intensity
conditioning, unrelated donors, and peripheral blood stem
cells among patients with grade III-IV acute GVHD increased
over time. In the unadjusted analysis, 12-month OS increased
over time (28% in 1997-2001, 35% in 2002-2006, 48% in
2007-2012, P ¼ 0.004) reﬂecting a decrease in 12-month
GRM (54% in 1997-2001, 51% in 2002-2006, 31% in 2007-
2012, P¼ 0.0001) and improvement in 12-month PFS (27% in
1997-2001, 30% in 2002-2006, 42% in 2007-2012, p ¼ 0.02).
After multivariate analysis, the period of transplantation
remained a strong predictor for OS, and the hazard ratio
(HRs) in 1997-2001 and 2002-2006 compared with 2007-
2012 were 1.55 (95% CI, 1.0-2.3, p ¼ 0.03), and 1.54 (95% CI,
1.2-2.1, p¼ 0.004), respectively. Similarly, more recent period
of transplantation remained a signiﬁcant predictor for lower
GRM [HRs in 1997-2001 and 2002-2006 compared with
2007-2012 were 1.65 (95% CI, 1.0-2.6, p¼0.04), and 2.28 (95%
CI 1.6-3.3, p < 0.001)] and longer PFS [HRs in 1997-2001 and
2002-2006 compared with 2007-2012 were 1.5 (95% CI, 1.0-
2.2, p ¼ 0.04), and 1.49 (95% CI 1.1-2.0, p ¼ 0.007)].
Conclusion: The outcomes of patients who develop grade III
or IV acute GVHD after allogeneic HSCT has improved over
time with lower GRM and improvement in PFS and OS. Our
results suggest that the multiple innovations in trans-
plantation care have led to improved outcomes in patients
with grade III and IV acute GVHD, and outcomes are not as
poor as historically reported.413
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The 2005 NIH chronic GVHD organ and overall clinical
severity score is based on the assessment of current status
regardless of whether abnormalities are caused by chronic
GVHD or other conditions. The score assignment does not
require knowledge of past manifestations, attribution, or
whether GVHD is still active; it simply describes the patient’s
current condition. The aim of this prospective study was to
analyze confounding factors affecting organ-speciﬁc 0-3
scores and global severity scores in patients with chronic
GVHD.
Patients and Methods: All 139 patients with NIH chronic
GVHD evaluated at our center between January and
September 2013 were included in this study. Medical pro-
viders completed the NIH 0-3 organ-speciﬁc scoring form
with two additional questions for each organ to identify
abnormalities that were 1) not attributed to chronic GVHD
(yes/no), or 2) attributed to chronic GVHD plus other causes
(yes/no). Causes of abnormalities attributed to causes other
than GVHD were described by the medical evaluator.
Results: Sixty-nine (50%) of the 139 patients had abnor-
malities attributed only to chronic GVHD. Fifty-nine (42%)
patients had abnormalities not attributed to chronic GVHD in
at least 1 organ, and 24 (17%) had abnormalities attributed to
chronic GVHD plus other causes in at least 1 organ. The
distribution of organ involvement according to attribution of
Table
Distribution of organ involvement according to attribution of abnormalities
Normal
N (%)
Abnormalities
attributed
only to GVHD
N (%)
Abnormalities
attributed to
GVHD plus
other causes
N (%)
Abnormalities
attributed
only to other
causes
N (%)
Skin 55 (40) 63 (45) 4 (3) 17 (12)
Mouth 70 (50) 64 (46) 4 (3) 1 (1)
Eyes 71 (51) 59 (42) - 9 (7)
GI tract 110 (79) 15 (11) 3 (2) 11 (8)
Liver 99 (71) 27 (19) 8 (6) 5 (4)
Lungs 97 (70) 18 (13) 3 (2) 21 (15)
Joint 97 (70) 32 (23) 3 (2) 7 (5)
Genital 123 (89) 10 (7) 2 (1) 4 (3)
Figure. Distribution of global severity scores according to NIH chronic GVHD
consensus criteria with and without confounders
Figure 1. Engraftment of human cells in NSG mice
Lung or liver from NSG mice 8 weeks post transplantation were examined for
human CD4, CD8, CD20 and CD68 engraftment by IHC. Three randomly
selected sections per slide were observed under the x40 objective. Data were
calculated as: % positive cells ¼ positive nuclei cells Ú total cells nuclei x 100.
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attributed to chronic GVHD were observed most frequently
in lungs, gastrointestinal tract and skin sites. The most
common causes of abnormalities attributed to other causes
than GVHD included: conditions prior to the transplant,
sequela from prior GVHD, deconditioning, infections and
medications. When scores for organs or sites with abnor-
malities attributed to other than chronic GVHD were
rescored as zero, the global severity score shifted downward
from mild (n¼7), moderate (n¼2), and severe (n¼1) to none
and from moderate (n¼8) and severe (n¼1) to mild (Figure).
Conclusion: A modest downward shift of the global severity
score occurs when confounders are taken into account in the
0-3 organ-speciﬁc scoring system. Our ﬁndings support the
need for clariﬁcation of the NIH diagnosis and staging
consensus criteria.414
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PBMCs can develop xenogeneic acute graft-versus-host dis-
ease (aGVHD), which mimics human aGvHD manifestations,
including skin or liver involvement. In contrast little is
known about the chronic GVHD (cGVHD) mouse model,
although a recently described humanized cGVHD model
using NSG mice with human thymocytes showed liver
ﬁbrosis 14 weeks after transplantation. Here, we established
a humanized cGVHDmodel with chronic lung inﬂammation
and ﬁbrosis mimicking human cGvHD 8 weeks post
transplantation.
Material and Method: NSGmicewere recipients and treated
with cyclophosphamide (Cy) at different doses (20-120mg/
kg) at day -3 and -2 plus 200cGy X-ray at day-1 followed by
injection of 1-5x106 G-CSFmobilized human PBMCs or 1x105
CD34+ cells at day 0. Samples of skin, lung, liver, spleen and
small intestine were taken 8 weeks post transplantation, and
ﬁxed in 10% neutral-buffered formalin, embedded in parafﬁn,
sectioned, slide mounted, and stained with hematoxylin and
eosin and Masson’s trichrome. Specimens were evaluated
blinded by a pathologist. Engraftment was assessed in pe-
ripheral blood by ﬂow cytometry and in each organ by
immunohistochemistry (IHC) using anti-human CD4/8/20/
68 antibodies.
Result: Mice that received over 60mg/kg of Cy lost weight
and died earlier than those receiving 20mg/kg or less. Sub-
sequently we used 20mg/kg Cy combinedwith 200cGy TBI as
conditioning for the study. Mice receiving 5x106 PBMCs
exhibited acute illness including hunching or rufﬂed hair and
died earlier compared with mice receiving 1x106PBMCs. IHC
analysis revealed engraftment of CD4, CD8 T cells, CD20+ B
cells but not CD68+ cells in the lung, liver, skin or spleen
(Figure 1). Analysis at 8 weeks post-transplantation showed
that themice receiving 1x106PBMCs exhibited aggregation of
